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Abstract
We have undertaken a systematic Mendelian randomization (MR) study using methylation quantitative trait loci (meQTL) as
genetic instruments to assess the relationship between genetic variation, DNA methylation and 139 complex traits. Using
two-sample MR, we identified 1148 associations across 61 traits where genetic variants were associated with both proximal
DNA methylation (i.e. cis-meQTL) and complex trait variation (P<1.39  1008). Joint likelihood mapping provided evidence
that the genetic variant which influenced DNA methylation levels for 348 of these associations across 47 traits was also
responsible for variation in complex traits. These associations showed a high rate of replication in the BIOS QTL and
UK Biobank datasets for 14 selected traits, as 101 of the attempted 128 associations survived multiple testing corrections
(P<3.91  1004). Integrating expression quantitative trait loci (eQTL) data suggested that genetic variants responsible for
306 of the 348 refined meQTL associations also influence gene expression, which indicates a coordinated system of effects
that are consistent with causality. CpG sites were enriched for histone mark peaks in tissue types relevant to their associated
trait and implicated genes were enriched across relevant biological pathways. Though we are unable to distinguish mediation
from horizontal pleiotropy in these analyses, our findings should prove valuable in prioritizing candidate loci where DNA
methylation may influence traits and help develop mechanistic insight into the aetiology of complex disease.
Introduction
The majority of genetic variants associated with complex traits
are located in non-coding regions of the genome and therefore
likely to influence disease via gene regulation (1). To improve
our understanding of these mechanisms, information about ge-
netic variants associated with gene expression (also known as
expression quantitative trait loci, eQTL) is now commonly in-
corporated with complex traits and diseases (2–4). Recently, this
type of methodology has been extended to integrate epigenetic
data using genetic variants associated with DNA methylation lev-
els (known as methylation quantitative trait loci, meQTL) (5,6). In
this study, we have built on previous work to prioritize CpG sites
which may play a mediatory role along the causal pathway from
genetic variation to complex trait and disease susceptibility.
As with complex traits, DNA methylation levels at CpG sites
across the genome can be determined by both genetic and
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environmental factors. Moreover, observational associations be-
tween complex traits and DNA methylation are prone to con-
founding and reverse causation, which can undermine our
ability to infer causal relationships (7,8). An approach to address
this limitation is Mendelian randomization (MR), a method by
which the causal inference of one trait (the exposure) on an-
other trait (the outcome) can be inferred. This is achieved by us-
ing genetic variants known to robustly associate with the
exposure as instrumental variables (9,10). The sample size of
studies with data on epigenome-wide DNA methylation,
genome-wide genetic data and complex traits are modest com-
pared with most genetic association studies of complex traits,
primarily due to the current costs of DNA methylation arrays.
A recent methodological development to circumvent this limita-
tion is two-sample MR (2SMR), an approach where summary sta-
tistics for the effect of genetic instruments on exposure and
outcome are obtained from two separate studies (11,12). 2SMR
enables causal relationships to be investigated without requiring a
sample of individuals with genotype, exposure and outcome data.
As described in our previous work (6), when a genetic variant
is reliably associated with both DNA methylation and complex
trait variation, we postulate that there are four possible scenar-
ios that may account for this (Fig. 1):
1) The genetic variant has a causal effect on the complex trait
which is mediated by changes in DNA methylation.
Figure 1. Explanations evaluated which may potentially explain associations between meQTL and trait outcomes. (1) The genetic variant has a causal effect on the
complex trait which is mediated by changes in DNA methylation. (2) The genetic variant that influences DNA methylation is in LD with another variant that influences
complex trait variation. (3) The genetic variant has a causal effect on the complex trait which subsequently influences DNA methylation at this locus. (4) The genetic
variant influences DNA methylation and the complex trait via two independent biological pathways (also known as horizontal pleiotropy).
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2) The genetic variant responsible for changes in DNA methyl-
ation is in linkage disequilibrium (LD) with the genetic vari-
ant that influences complex trait variation.
3) The genetic variant has a causal effect on the complex trait
(or a related complex trait which resides along the causal
pathway to disease) which subsequently influences DNA
methylation at this locus.
4) The genetic variant influences DNA methylation and the
complex trait via two independent biological pathways
(also known as horizontal pleiotropy).
A search for examples where explanation 1 could be true is
performed by evaluating associations between known meQTLs
and complex traits. DNA methylation is typically instrumented
by a single cis-acting variant, which means that an unreliable MR
estimate of causality may arise due to the causal variant for
DNA methylation simply being in LD with a causal variant for
the complex trait (explanation 2). The chances of this occurrence
are dramatically increased when investigating causal relation-
ships systematically as undertaken in our framework. We at-
tempt to distinguish between explanations 1 and 2 using genetic
colocalization methods, such as joint likelihood mapping (JLIM),
evaluating whether the underlying genetic variation at a geno-
mic region is responsible for effects on both an intermediate and
complex trait (13). Genetic colocalization approaches such as
JLIM are necessary, but not sufficient, for causality.
We then attempt to distinguish between explanations 1 and 3
by obtaining instruments for the complex traits and testing the op-
posite direction of effect (14,15). Using a single cis-acting instrument
also means that we are unable to reliably distinguish between me-
diation (explanation 1) and horizontal pleiotropy (explanation 4).
Nevertheless, within our framework we use MR to investigate the
relationship between DNA methylation and gene expression at loci
where mediation is a potential explanation for shared genetic
effects. In doing so, we aim to identify a coordinated system of
effects through shared genetic variation of molecular phenotypes.
In this study, we have adapted our analytical framework devel-
oped previously to map putative causal relationships between
DNA methylation and 139 complex traits taken from large-scale
consortia using a two-sample framework (16). We build on previ-
ous work (5) by extending the survey to a much larger number of
traits, interrogating bi-directional relationships, integrating gene
expression data into analyses and undertaking exhaustive JLIM
analyses to investigate linkage as an explanation for identified
effects. Effect estimates on DNA methylation were obtained from
the Accessible Resource for Integrated Epigenomics Studies
(ARIES) project, which consists of individuals enrolled in the Avon
Longitudinal Study of Parents and Children (ALSPAC). Effects on
complex traits were obtained using findings from large-scale ge-
nome-wide association studies (GWAS). Replication of results with
evidence of a putative causal relationship for a selection of traits
was undertaken using DNA methylation data from the BIOS QTL
browser (17) and complex trait data from up to 334 398 individuals
enrolled in the UK Biobank study (18). Functional annotation and
enrichment analyses, including data for histone mark peaks and
DNAse I hypersensitivity sites across 113 different tissue types,
were undertaken for selected variants and CpG sites (19,20).
Results
Systematic search for putative mediation of genetic
influences on complex traits through DNAmethylation
The initial analysis involved over 4.2 million MR analyses to
evaluate the potential causal relationship between DNA
methylation at 30 328 CpG sites and 139 complex traits using
MR-Base (16). We only investigated CpG sites using cis-meQTL
(i.e. genetic instruments within 1MB distance of their associated
CpG site) in order to improve the specificity of the instruments.
Subsequently the majority of CpG sites were instrumented
using a single cis-acting meQTL (n¼ 26 975) and therefore MR ef-
fect estimates were calculated using the Wald ratio (21). When
more than one instrument was available the inverse variance
weighted (IVW) method was used instead (22).
MeQTL effects were typically identified at multiple time
points across the life course in ARIES, and therefore we only
used effect estimates from a single time point to reduce the bur-
den of multiple testing. A list of the complex traits analysed can
be found in Supplementary Material, Table S1, which were se-
lected based on GWAS with effect estimates from over 100 000
genetic variants, sample sizes of over 1000 individuals and un-
dertaken in either European or mixed populations. The MR-Base
platform was then used to evaluate the association between our
exposure (i.e. DNA methylation levels at a CpG site) and our out-
come (i.e. a complex trait). When meQTL effects were obtained
from a time point in ARIES which is later in the life course com-
pared with the analysed outcome (e.g. childhood obesity),
results should be interpreted as evidence of genetic liability be-
tween DNA methylation and complex trait.
There were 1148 putative MR associations between a CpG
site and complex trait which survived the multiple testing
threshold across 61 different traits (P< 1.397  1008,
Supplementary Material, Table S2). A heat map visualizing the
correlation of the z scores from the MR analysis across traits
can be found in Supplementary Material, Figure S1, which high-
lights traits which may be influenced by changes in DNA meth-
ylation at shared loci.
Identifying shared genetic variants between DNA
methylation and complex traits
Results surviving multiple testing in the previous analysis may
arise due to an meQTL and trait-associated variant overlapping
at a genomic locus due to chance. To investigate this, we ap-
plied the JLIM algorithm (13) which tests whether variation in
two traits (i.e. DNA methylation and a complex trait in this
study) are driven by a shared causal effect [with the caveat that
two causal variants in perfect LD (i.e. r2 ¼ 1) cannot be investi-
gated using such methodology). This is obtained by generating
a permutation-based null distribution for a trait with
individual-level data (i.e. DNA methylation in our analysis) and
assessing the likelihood that the causal variant for this trait is
also responsible for variation on a different trait based on
summary-level data (i.e. GWAS results for a complex trait).
Permutation testing was implemented by the JLIM method to
account for the 1148 associations identified in the previous
analysis (P< 4.36  105). The JLIM analysis suggested that 348
of the 1148 CpG-trait associations were due to methylation and
complex trait variation both being influenced by the same un-
derlying genetic variant (Supplementary Material, Table S3). We
refer to these 348 associations hereafter as ‘CpG-trait
associations’.
Consequently, the 800 associations which did not provide
evidence from JLIM in this evaluation were likely due to the
causal variant for DNA methylation being in LD with a separate
variant responsible for complex trait variation. Figure 2 illus-
trates findings for 2 of the 61 traits which had at least one effect
that survived the multiple testing threshold, where individual
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points represent P-values from the 2SMR analysis. Points
highlighted in red correspond to loci where JLIM provided evi-
dence that the same underlying causal variant influences both
DNA methylation and complex trait. For example, the results il-
lustrated in Figure 2B suggest that the same causal variants at
the SLC12A4, FADS1 and ANGPTL4 loci are responsible for
changes in both proximal DNA methylation and high-density li-
poprotein (HDL) cholesterol. In contrast, results suggest the ge-
netic variant driving the observed effect on HDL cholesterol at
the LPL gene region is not responsible for changes in DNA meth-
ylation at this locus. Manhattan plots for all 61 traits can be
found in Supplementary File 1.
Reverse Mendelian randomization
For the 348 CpG-trait associations identified in the previous
analysis, we performed reverse MR to test if the CpG-trait asso-
ciations arose due to traits influencing CpG levels. This was un-
dertaken by modelling a complex trait as our exposure and DNA
methylation levels at a CpG as our outcome. The only evidence
of association in the reverse MR analysis was between number
of cigarettes smoked per day and DNA methylation variation at
the CHRNA5/PSMA4 region (Supplementary Material, Table S4).
However, this complex trait currently only has a single genetic
instrument which weakens our ability to robustly investigate di-
rection of effect for this result.
The reverse MR analysis was only undertaken for CpG-trait
associations detected in the initial analysis due to the antici-
pated reduction in power when analysing DNA methylation as
our outcome. This is highlighted by comparing the average ab-
solute effect estimates obtained from the results of the CpG-
trait MR at these CpG sites (beta ¼ 0.216, se ¼ 0.026) against the
reverse MR (beta ¼ 0.269, se ¼ 0.263). The lack of associations
identified by this analysis is therefore likely due to sample sizes
in ARIES, given that similar approaches have identified evidence
that complex traits influence DNA methylation using larger
samples and methods that require individual level data (23).
Validation of findings using data from the BIOS QTL
browser and UK Biobank study
We undertook a replication analysis for the 128 CpG-trait asso-
ciations for which independent data was available, repeating
analyses using meQTL data from the BIOS QTL browser (17) and
complex trait data from the UK Biobank (Supplementary
Material, Table S5) (18). There was evidence of replication for
101 of the 128 associations based on multiple testing corrections
(P< 3.91  1004) and the direction of effect between DNA meth-
ylation and complex traits (Supplementary Material, Table S6).
Evaluating the relationship between DNAmethylation
and gene expression
We integrated gene expression data to investigate whether the
genetic variants used to identify CpG-trait associations were
known to influence gene expression as well as DNA methyla-
tion. Data from the GTEx consortium (24) and the blood eQTL
browser (25) suggested that this was the case for 306 of the 348
CpG-trait associations. 2SMR was used to evaluate the relation-
ship between DNA methylation and gene expression at each of
these loci, i.e. whether higher DNA methylation associates
with higher or lower gene expression (Supplementary Material,
Table S7).
These results also provide some biological insight regarding
tissue specificity and how this varies for different loci.
Figure 2. Manhattan plots illustrating results of two-sample MR analysis between epigenome-wide DNA methylation and (A) educational attainment (top) and (B) HDL
cholesterol (bottom). Points represent –log 10 P-values (y-axis) for CpG sites (genomic location on the x-axis) as evaluated using two-sample MR analysis between DNA
methylation (as our exposure) and complex traits (as our outcome) using meQTL as genetic instruments. Effects that survive the multiple testing threshold in our
analysis (P < 1.397  1008—represented by the red horizontal line) are annotated using mapped genes according to Illumina (or nearest gene when no gene has been
reported by Illumina). Effects where JLIM suggested the causal variant for DNA methylation and complex trait variation were the same are highlighted in red.
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For example, the effect between ADIPOQ gene expression and
adiponectin was only observed using adipose subcutaneous
data, which is a relevant tissue type for this trait. In contrast,
the effect between ABO gene expression and various complex
traits was found across 24 different tissue types, which can help
explain why variation at this region was associated with multi-
ple traits. A summary of the associations detected at each stage
of the analysis in the study can be found in Table 1.
Gene prioritisation, implicated biological pathways and
druggable targets
A suite of bioinformatics tools was used to calculate the pre-
dicted consequences and severity for genetic variants responsi-
ble for CpG-trait associations (Supplementary Material, Table S8).
Likely impacted genes for CpG-trait associations were prioritized
using DEPICT (26) (Supplementary Material, Table S9).
Annotated genes were grouped into categories based on
their associated trait (Supplementary Material, Table S10). Each
group of genes was then analysed in turn using
ConsensusPathDB (27) to test whether likely implicated genes
were enriched for biological pathways (Supplementary Material,
Table S11) and gene ontology terms (Supplementary Material,
Table S12) based on a false discovery rate < 5%. Overall there
were 64 enriched pathway effects and 232 enriched GO term
effects. Amongst these enrichments are biologically meaningful
results, such as genes associated with cardiovascular traits be-
ing enriched for lipid and metabolic processes, whereas genes
associated with autoimmune traits are enriched for immune
system pathways and terms.
Prioritised genes were also evaluated for druggability using
the ChEMBL database (28) (version 23 accessed on 13 June 2017).
Proteins encoded by implicated genes which are targets for
therapeutic intervention were identified (Supplementary
Material, Table S13). These included approved drugs, such as
estropipate and estradiol cypionate, which targets ESR1 (associ-
ated with HDL cholesterol and birth weight), as well as com-
pounds in development, such as cyclin-dependent kinase
inhibitors, which target CDK12 (associated with HDL cholesterol
and serum creatinine).
Tissue-specific enrichment for CpG sites
CpG sites implicated in CpG-trait associations were annotated
to determine whether they reside in regulatory regions using
data from Illumina and Ensembl (29). DNAse I and histone mark
peak data across 113 different tissue types from the ENCODE
and the Roadmap Epigenomics projects was also used to anno-
tate CpG sites (19,20). CpG sites were then grouped according to
the category of their associated trait (Supplementary Material,
Table S10) and tested for enrichment after removing proximal
probes which may be co-methylated (Supplementary Material,
Tables S14–22). In particular, evidence of enrichment for
H3K4me1 histone marks was observed for associated CpG sites,
as well as evidence of enrichment in tissue types relevant for
associated traits. For instance, the top hit for autoimmune traits
was observed for H3K4me1 marks in spleen tissue, whereas the
top hit for haematological traits was observed for H3K4me1
marks in primary haematopoietic cells. Heat maps illustrating
these results for histone mark peaks across different tissue
types can be found in Supplementary Material, Figure S2.
Discussion
In this study we have extended an analytical framework to sys-
tematically evaluate the potential causal relationship between
DNA methylation and complex traits using GWAS summary
data. We identified 348 associations where CpG sites and com-
plex disease share genetic influences. Although we are unable
to robustly demonstrate that these effects occur along a com-
mon causal pathway to disease (e.g. the associations could be
compatible with horizontal pleiotropy), we found that 306 of
these associations also share genetic loci which influence gene
expression. The genes impacted by changes in DNA methyla-
tion at these CpG sites represent promising candidates to ex-
plore the potential mediatory role of epigenetic modifications
and their potential downstream effects on disease aetiology.
An attractive advantage of using 2SMR to investigate
CpG–trait relationships is that it circumvents the requirement
of having both intermediate and complex traits measured
in the same sample. For instance, a recent epigenome-wide
Table 1. Overview of the main findings from the various stages of this study
Analysis Objective Number of tests
undertaken
Number of results surviving
multiple testing
Two-sample MR (CpG ->
complex trait)
Identify potential CpG sites where DNA methylation
may mediate the influence of genetic variants on
complex traits
4 215 592 1148
Joint likelihood mapping Assess the likelihood that results from the previous
analysis are observed due to two separate causal
variants which are in LD with one and other
1148 348
Reverse two-sample MR
(complex trait -> CpG)
Evaluate potential evidence for reverse causation,
i.e. complex trait influences DNA methylation
levels
348 2a
Replication two-sample MR Validate results for 14 complex traits using data
from the BIOS QTL browser and UK Biobank study
128 101
Two-sample MR (CpG ->
gene expression)
Investigate whether meQTL used as instruments in
the initial analysis overlap with variants known to
influence nearby gene expression (i.e. whether
they are also cis-eQTL)
348 306
aBoth effects observed in the reverse MR analysis were based on a single genetic instrument, similar to findings in the initial MR at these loci (CpG -> complex trait).
We are therefore unable to robustly distinguish the direction of effect between methylation and complex trait for these associations.
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association study (EWAS) of lipids used a sample size of 725
individuals in their discovery analysis to identify two CpG sites
associated with HDL cholesterol (30). However, as illustrated in
the bottom plot of Figure 2, using findings from a large-scale ge-
netic association study (with approximately 190 000 individuals)
we have discovered nine genetic loci (which are different to the
two identified in the aforementioned EWAS), which may influ-
ence HDL cholesterol variation via changes in DNA methylation.
Furthermore, by using genetic instruments we avoid the com-
mon pitfalls in observational studies (e.g. EWAS) of confounding
and reverse causation. An example of this can be found by con-
trasting the top plot in Figure 2 with results from a recent EWAS
of educational attainment, which identified associations at nine
CpG sites that were all previously associated with cigarette
smoking (31). Although educational attainment may be an
underlying cause of these changes in methylation levels (i.e.
educational attainment influences smoking behaviour), such
claims cannot be made with confidence in the presence of con-
founding factors. In contrast, none of the six independent CpG
sites linked with educational attainment in this study are asso-
ciated with exposure to cigarette smoking. This is based on find-
ings from the largest smoking EWAS to date of both own
smoking (32) and exposure to maternal smoking in utero (33).
The framework used in this article is unlikely to be able to
uncover novel trait-associated loci in the field of GWAS because
the experiment-wide multiple testing correction is similar to
the canonical GWAS significance threshold. But the framework
can potentially uncover evidence suggesting that changes in
DNA methylation may influence traits at these loci. In terms of
specific loci detected in our framework where this may be the
case, we have been able to support previously reported findings
as well as build upon them. For instance, there is increasing evi-
dence that changes in DNA methylation may influence cardio-
vascular traits at the ADCY3, ADIPOQ and FADS1 loci, which
supports results detected by previous studies (5,6). However, by
using meQTL data derived from a larger sample of individuals
and also GWAS data for a far greater number of complex traits,
we have been able to detect novel loci where DNA methylation
may play a role in disease susceptibility. For example, previous
findings have only implicated CpG sites on chromosome 6, pre-
dominantly in the MHC region, with risk of rheumatoid arthritis
(34). In our study, there were six novel loci outside of this region
where genetic variation may influence rheumatoid arthritis risk
via changes in DNA methylation (TTC34, MMEL1, AFF3, IRF5,
CXCR5 and PGAP3). Furthermore, our pathway and gene ontol-
ogy enrichment analyses provide evidence that sets of genes
detected in our study may collectively influence disease. For
example, the strongest evidence of pathway enrichment for au-
toimmune-related genes was for the inflammatory bowel dis-
ease pathway according to the Kyoto Encyclopaedia of Genes
and Genomes database (35). This effect was driven by the
STAT3, IL18R1 and SMAD3 genes which have previously been
implicated in inflammatory bowel disease (36–38).
In this study, we have used DNA methylation derived from
blood to investigate its effect on a range of complex traits,
although epigenetic processes are known to be tissue specific
(39,40). For instance, we have identified association signals for
cognitive and neurological traits where we may expect the
causal genes to be expressed in brain tissue. However, studies
have demonstrated that the correlation between DNA methyl-
ation in measures of blood and brain is stronger than can be
accounted for by chance (41,42). This supports the validity of
the findings presented in this study for traits where blood may
not be a relevant tissue, although we suggest that in-depth
tissue-specific evaluations are necessary to explore these fur-
ther. Further evaluations are also warranted to investigate
temporal relationships between DNA methylation and com-
plex traits. For instance, in this study the meQTL we used had
effect sizes that were typically consistent across the five time
points within the ARIES project. We have included all meQTL
results for all five time points for the 348 associations identi-
fied in this study in Supplementary Material, Table S23 to illus-
trate this point. We find only two meQTL were associated at
only a single time point. This could help facilitate future analy-
ses which investigate how early in the life course changes in
DNA methylation may occur with respect to disease
progression.
The 450K Illumina Infinium Beadchip array used to generate
the DNA methylation data in this study only covers 1.7% of
the 29 million CpG sites across the human genome. This sug-
gests that a wealth of unmeasured data remains unexplored
within this paradigm. Furthermore, although we have demon-
strated the value of our analytical framework to investigate the
role of DNA methylation in disease, we anticipate future studies
will have success by investigating other intermediate traits in a
similar manner, such as histone marks, metabolites and pro-
teins. These endeavours will be valuable in uncovering signals
which reflect a coordinated system of causality, as well as
helping pinpoint the true causal gene at densely populated
gene neighbourhoods. They should also prove particularly valu-
able to help identify and evaluate targets for therapeutic
intervention.
Studies with increasingly large sample sizes with ‘omic’ data
will also allow more robustly associated QTL across different
omics types to be uncovered across the genome. This will be
hugely beneficial for frameworks such as the one portrayed in
this study as it should improve causal inference amongst inter-
mediate traits and downstream implications on disease suscep-
tibility. Moreover, using multiple instruments can improve our
ability to separate mediation from horizontal pleiotropy as the
putative mechanism underlying the association (43–45). The in-
tegration of colocalization methods to assess whether changes
in DNA methylation and complex traits are driven by shared
causal variants will remain important to implement. In this
study, we have been able to use the JLIM method due to having
individual level data on epigenome-wide DNA methylation
from the ARIES project. Future endeavours, which may be
restricted to using summary-level data for omics trait, are able
to utilize viable alternatives, such as the HEIDI (heterogeneity in
dependent instruments) (2) and ‘coloc’ (46) methods. An illus-
tration of the importance of such approaches can be found
when evaluating the results at the ABO locus in our study. In
the initial MR analysis, there were association signals with
seven different traits at this locus, although after applying the
JLIM method only detected associations with haemoglobin con-
centration, red blood cell count and myocardial infarction
remained.
A limitation of using 2SMR is that the statistical power is
determined by the sample size used to generate effect esti-
mates on the outcome variable. In this study, we therefore
only applied the reverse MR analysis at loci identified in the
initial analysis (i.e. loci where a SNP already exhibits a large
enough effect on a complex trait for it to be an meQTL).
Nonetheless, we did not identify strong evidence that complex
traits influence DNA methylation levels in our reverse MR
analysis, although this approach is likely to yield insightful
findings as larger samples with 450K data become accessible.
However, subsequent studies which investigate this need to
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take into complex trait incidence. For example, in the ARIES
cohort it is unlikely that incidence of coronary heart disease
would have been frequent enough to identify a true causal ef-
fect on DNA methylation regardless of sample size. Therefore
results can only be regarded as an association of the disease/
trait liability as opposed to causality. Furthermore, effect esti-
mates for the instrumental variables used in our study were
obtained from the same sample that they were identified in.
Future studies which have access to meQTL data from multiple
cohorts should also benefit from identifying instruments in a
separate dataset to those which effect estimates are derived
from to reduce the influence of winner’s curse on the MR effect
estimates.
The results presented in this study are likely only the tip of
the iceberg for candidate loci which may influence complex
traits via epigenetic mechanisms. Thorough evaluations of
these loci are necessary to determine the extent to which
these processes play a role in complex disease risk. A wealth of
data on intermediate omic traits are expected to be generated
in large sample sizes across multiple tissue types in forthcom-
ing years. MR can be used to evaluate relationships between
these intermediate traits and help develop our understanding
of the putative causal pathway from genetic variation to
disease.
Materials and Methods
Overview
In this study we attempt to create a mapping of SNPs known to
influence DNA methylation levels that also influence complex
traits. Such a relationship is necessary (but not sufficient) for
DNA methylation to lie on the causal path from genetic poly-
morphisms to complex traits. We build on a previously de-
scribed analytical strategy by expanding the analysis to a large
number of complex traits and diseases. Briefly, we use previ-
ously published results from meQTL studies to test 30 328 CpG
sites with known genetic factors (the ARIES dataset, a subset of
participants from ALSPAC). Each CpG site is tested for associa-
tion with each of 139 complex traits, using published GWAS
summary data that were compiled in the MR-Base database.
Putative findings are replicated using meQTL results from the
BIOS dataset and genetic associations with complex traits from
UK Biobank.
The Avon Longitudinal Study of Parents and Children
(ALSPAC)
ALSPAC is a population-based cohort study investigating genetic
and environmental factors that affect the health and develop-
ment of children. The study methods are described in detail else-
where (47,48) (http://www.bristol.ac.uk/alspac). Briefly, 14 541
pregnant women residents in the former region of Avon, UK, with
an expected delivery date between 1 April 1991 and 31 December
1992, were eligible to take part in ALSPAC. Detailed information
and biosamples have been collected on these women and their
offspring at regular intervals, which are available through a
searchable data dictionary (http://www.bris.ac.uk/alspac/research
ers/data-access/data-dictionary/).
Written informed consent was obtained for all study partici-
pants. Ethical approval for the study was obtained from the
ALSPAC Ethics and Law Committee and the Local Research
Ethics Committees.
Accessible Resource for Integrated Epigenomic Studies
(ARIES) project
Samples
The ARIES study is a subset of the participants in the ALSPAC
study. Blood samples were obtained for 1018 mother–offspring
pairs (mothers at two time points and their offspring at three
time points) (49). The Illumina HumanMethylation450 (450K)
BeadChip array was used to measure DNA methylation at over
480 000 sites across the epigenome.
Methylation assays
DNA samples were bisulfite treated using the Zymo EZ
DNA MethylationTM kit (Zymo, Irvine, CA). The Illumina
HumanMethylation450 BeadChip (HM450k) was used to measure
methylation across the genome and the following arrays were
scanned using Illumina iScan, along with an initial quality review
using GenomeStudio. A purpose-built laboratory information
management system (LIMS) was responsible for generating batch
variables during data generation. LIMS also reported quality con-
trol (QC) metrics for the standard probes on the HM450k for all
samples and excluded those which failed QC. Data points with a
read count of 0 or with low signal: noise ratio (based on a P-value
> 0.01) were also excluded based on the QC report from Illumina
to maintain the integrity of probe measurements. Methylation
measurements were then compared across time points for the
same individual and with SNP-chip data (HM450k probes clus-
tered using K-means) to identify and remove sample mismatches.
All remaining data from probes was normalized with the
Touleimat and Tost (50) algorithms using R with the wateRmelon
package (51). This was followed by rank-normalizing the data to
remove outliers. Potential batch effect were removed by regress-
ing data points on all covariates. These included the bisulfite-
converted DNA (BCD) plate batch and white blood cell count
which was adjusted for using the estimateCellCounts function in
the minfi Bioconductor package (52).
Genotyping assays
Genotype data were available for all ALSPAC individuals enrolled
in the ARIES project, which had previously undergone QC, clean-
ing and imputation at the cohort level. ALSPAC offspring selected
for this project had previously been genotyped using the Illumina
HumanHap550 quad genome-wide SNP genotyping platform
(Illumina, Inc., San Diego, CA, USA) by the Wellcome Trust Sanger
Institute (WTSI, Cambridge, UK) and the Laboratory Corporation
of America (LCA, Burlington, NC, USA). Samples were excluded
based on incorrect sex assignment; abnormal heterozygosity
(<0.320 or >0.345 for WTSI data; <0.310 or >0.330 for LCA data);
high missingness (>3%); cryptic relatedness (>10% identity by de-
scent) and non-European ancestry (detected by multidimensional
scaling analysis). After QC, 500 527 SNP loci were available for the
directly genotyped dataset. Following QC the final directly geno-
typed dataset contained 526 688 SNP loci.
Imputation
Genotypes with MAF > 0.01 and Hardy-Weinberg equilibrium
P> 5 107 were phased together using ShapeIt (version 2, revi-
sion 727) (53) and imputed using the 1000 Genomes reference
panel (phase 1, version 3, phased using ShapeIt version 2,
December 2013, using all populations) using Impute (v2.2.2) (54).
After imputation dosages were converted to bestguess geno-
types and filtered to only keep variants with an imputation
quality score  0.8. The final imputed dataset used for the anal-
yses presented here contained 8 074 398 loci.
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The meQTL database
Effects for genetic variants known to strongly associate with DNA
methylation (referred to hereafter as meQTL), as estimated using
the ARIES dataset in a previous study, were obtained from the
meQTL database (http://www.mqtldb.org/; date last accessed
September 9, 2017) (55). In this study we have only used meQTL
acting in cis (i.e. variants located within 1MB of their associated
CpG site) to reduce the risk of pleiotropy influencing our results, as
variants which are associated with methylation levels at multiple
loci across the genome may be more likely to impact independent
biological pathways simultaneously.
LD clumping was undertaken to identify independent
meQTL (r2 < 0.01) for each CpG site which could be used as
instrumental variables for MR analyses based on an inclusion
criteria of P< 1.0  107. Only cis-meQTL were evaluated (i.e.
SNPs associated with DNA methylation at a CpG site within a
1MB distance) as trans-meQTL may be more prone to horizontal
pleiotropy. Based on this, there were 30 328 CpG sites eligible for
analysis (26 975 CpG sites with 1 meQTL, 5984 CpG sites with 2
meQTLs, 969 CpG sites with 3 meQTLs, 140 CpG sites with 4
meQTLs and 3 CpG sites with 5 meQTLs). As effect estimates for
meQTL were typically consistent across time points in ARIES,
we only ran analyses once for each CpG site to reduce the bur-
den of multiple testing. This should therefore facilitate future
analyses for studies with specific hypotheses regarding tempo-
ral changes in DNA methylation. Supplementary Material,
Table S23 provides effects across all time points for SNP–CpG
combinations which were identified by our study. An overview
of the number of cis-meQTLs at each time point in ARIES along
with descriptive summary statistics can be found in
Supplementary Material, Table S24.
GWAS summary data for 139 complex traits and
diseases
We extracted effects of genetic variants on complex traits using
large-scale studies which were available within the MR-Base
platform (http://www.mrbase.org; date last accessed September
9, 2017) (16). We used the following inclusion criteria to select
complex traits to be analysed:
• Effects reported genome-wide for over 100 000 genetic
variants
• Study samples must be larger than 1000
• Either European or mixed populations
• Reported beta, standard error and effect alleles for variants
These criteria yielded 139 complex traits and diseases
(Supplementary Material, Table S1).
The BIOS QTL browser
The BIOS QTL browser contains results from meQTL analyses
in whole blood using a sample of 3841 Dutch individuals
(http://www.genenetwork.nl/biosqtlbrowser/; date last accessed
September 9, 2017) (17). The full list of primary cis-meQTLs was
downloaded to evaluate effects identified in the discovery MR
analysis conducted in ARIES.
The UK Biobank
Genotype data was available for approximately 490 000 individ-
uals enrolled in the UK Biobank study. Phasing and imputation
of this data is explained elsewhere (56). Individuals with with-
drawn consent, evidence of genetic relatedness or who were
not of ‘white European ancestry’ based on a K-means clustering
(K¼ 4) were excluded from analysis.
Phenotype data were collected for the following traits (with
their UK Biobank variable ID in brackets) which were identified
as suitable for replication due to their samples sizes after merg-
ing with genotype data (n> 1000); age at menarche (2714), age at
menopause (3581), asthma (22 127), birth weight (20 022), body
mass index (21 001), cigarettes smoked per day (3456), extreme
height (derived from 50), height (50), hip circumference (49),
myocardial infarction (41 202, ICD10 code ¼ I21 or I22), obesity
class 1 (derived from 21 001), type 2 diabetes (derived from 2443,
although this variable does not distinguish between diabetes
type), waist circumference (48), weight (21 002) and years of
schooling [derived from 6138 to calculate EduYears as described
by Okbay et al. (57)]. After exclusions there were up to 334 398
individuals with both genotype and phenotype data who were
eligible for analysis.
The GTEx consortium and blood eQTL browser
Tissue-specific eQTL data was downloaded the GTEx portal
(https://gtexportal.org/; date last accessed September 9, 2017)
(version v6p). When effect estimates for meQTL were not
available from GTEx we obtained estimates for a surrogate
variants (r2  0.8). Finally, when there was no surrogate
variants available we consulted the blood eQTL browser
(https://genenetwork.nl/bloodeqtlbrowser/; date last accessed
September 9, 2017) (25).
Statistical analysis
Identifying candidate loci for mediation by DNA methylation
2SMR was undertaken systematically to evaluate evidence of a
causal relationship between DNA methylation at all eligible CpG
sites and complex traits. In this initial analysis DNA methyla-
tion was treated as our exposure and complex traits as our out-
come, using meQTL as our instrumental variables. We used the
PhenoSpD method (58–60) to calculate the appropriate number
of independent traits to adjust our analysis for due to strong
correlation amongst certain traits (i.e. BMI and obesity). The
multiple testing threshold was calculated as 0.05 divided by the
derived number of independent tests. CpG sites for effects
which survived this threshold were annotated based on evalua-
tions of the 450K array (61,62). When only one genetic instru-
ment was available MR effect estimates are based on the Wald
ratio test (21):
b^Wald ratio ¼
b^YjZ
b^XjZ
seðb^Wald ratioÞ
¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
seðb^YjZÞ 2
b^XjZ
2 þ
b^YjZ
2
seðb^XjZÞ 2
b^XjZ
4 
2b^YjZcovðb^XjZ; b^YjZÞ
b^XjZ
3
vuuut
where b^ YjZ is the coefficient of the genetic variant in the re-
gression of the exposure (e.g. DNA methylation) and b^ XjZ is the
coefficient of the genetic variant in the regression of the out-
come (e.g. complex trait).
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Where two or more genetic instruments were available
for analysis we used the IVW method to obtain MR effect esti-
mates (22):
b^IVW ¼
P
kXk Yk r
2
YkP
kX
2
k r
2
Yk
se b^IVW
 
¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1P
kX
2
k r
2
Yk
s
Where X is our exposure, Y is our outcome and our genetic var-
iants are k (where k¼ 1,. . ., n).
We used the MR-Base database and software to conduct this
analysis. We provided the effect size estimates for the genetic
effects on CpGs, and then extracted the corresponding SNP
effects from the GWAS summary data of the complex trait out-
comes. The TwoSampleMR R package was used to interface
with the MR-Base database and to perform the IVW and Wald
ratio calculations. If meQTL effect estimates on a GWAS trait
are not available, MR-Base attempts to find a genetic variant in
strong LD (r2  0.8) with the relevant meQTL to act as a proxy.
Data harmonization is also undertaken to ensure that effect
estimates for SNPs are based on the same strand (i.e. the ‘effect
alleles’ for reported findings are the same). Results from 2SMR
analyses were illustrated as Manhattan plots using code derived
from the qqman package in R (63).
Distinguishing causal effects from genetic confounding due to
linkage disequilibrium
Results which survived the multiple testing threshold in the
previous analyses were evaluated using the joint likelihood
method (JLIM) (13). The JLIM method evaluates whether the
same underlying genetic variation is responsible for effects
on two traits (i.e. DNA methylation at a CpG site and a com-
plex trait in this study). This is achieved using individual-
level data for one trait, which was DNA methylation levels
obtained from the ARIES project in this study, to generate a
permutation-based null distribution. The number of permuta-
tions required by the JLIM method was determined by number
of tests undertaken (i.e. the number of associations which
survived the P-value threshold in the previous analysis). A
lack of evidence (i.e. P< 0.05/number of associations evalu-
ated) in this analysis would suggest that the causal variant for
methylation variation was simply in LD with the putative
causal variant for the trait (thus introducing genetic con-
founding into the association between DNA methylation and
complex trait).
The JLIM approach was selected over alternative colocaliza-
tion methods [such as the HEIDI (heterogeneity in dependent
instruments) (2) and ‘coloc’ methods (46)] as in this study we al-
ways had individual-level data for one of the traits being
assessed (epigenome-wide DNA methylation levels from the
ARIES project) and therefore did not have to rely on availability
of summary statistics for both traits. The authors of the JLIM
method also demonstrate strong overall performance compared
with alternative approaches, although they do specify two limi-
tations to ensure accurate detection of shared genetic effects
between two traits. These limitations are that their resolution
becomes limited when (1) at high LD levels (i.e. r2  0.8) between
multiple causal instruments and (2) when the QTL effect (i.e.
meQTL in this study) is very weak (i.e. P> 0.01). These were
addressed in our study as we only used multiple instruments
within the MR analysis that were independent (r2 < 0.01) and
strongly associated with DNA methylation (P< 1.0  107).
Reverse Mendelian randomization
For CpG-trait effects identified in the previous analysis, we also
used 2SMR to evaluate evidence of genetic liability by modelling
complex traits as our exposure and DNA methylation as our
outcome. Instruments for complex traits were selected based
on a threshold of 5.0  1008 from large-scale GWAS after LD
clumping to identify independent variants. The IVW method
was applied to estimate the causal effects of traits on CpG sites
where more than one instrument was available, otherwise the
Wald ratio was used.
Replication of effects using the BIOS QTL browser and UK Biobank
For CpG-trait associations where DNA methylation and complex
trait were driven by the same causal variant, as inferred by the
JLIM method, we repeated our initial analysis using meta-
analysed meQTL data from the BIOS QTL browser (17) and trait
data from the UK Biobank project (18).
This validation analysis was undertaken for associations
across 14 traits from the full release of the UK Biobank project
for which large sample sizes (n 10 000) were available after
merging with available genetic data (Supplemental Material,
Table S4) (18). Linear or logistic regression was used (depending
on whether the trait was continuous or binary respectively) to
determine effect estimates of genetic variants on complex traits
adjusted for age, sex, the first 10 principal components and a
binary indicator which reflects which genotype chip individuals
were measured on. This was because a subset of UK Biobank
individuals had their genotype measured on the Affymetrix UK
BiLEVE Axiom array (50 000 participants), whereas the remain-
der were measured using the Affymetrix UK Biobank Axiom
array.
Causal relationship between DNA methylation and gene expression
We undertook 2SMR to evaluate the relationship between DNA
methylation and gene expression for effects where the causal
variant, as indicated by the JLIM method described above, was
both an meQTL and eQTL. Effect estimates for variants on gene
expression were obtained from the GTEx consortium v6p
(www.gtexportal.org/; date last accessed September 9, 2017)
(64). When effect estimates for the putative causal variant were
not available from GTEx we identified a surrogate variant in-
stead (r2  0.8). Where no surrogate was available within GTEx
we consulted the blood eQTL browser (http://genenetwork.nl/
bloodeqtlbrowser/; date last accessed September 9, 2017) (25).
Functional informatics
Variant annotation and gene prioritization
Genetic variants for effects potentially mediated by changes in
DNA methylation were analysed using the variant effect predic-
tor (VEP) (65) to calculate their predicted consequence.
Regulatory data were obtained from Ensembl (www.ensem-
bl.org/; date last accessed September 9, 2017) (29) to evaluate
whether these variants reside within regulatory regions of the
genome.
Prior to enrichment analyses and gene prioritization, as
effects were grouped together as opposed to evaluated individu-
ally, we removed effects involving CpG sites flagged for exclu-
sion based on evaluations by Zhou et al. (62) and Naeem et al.
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(61). This was based on their criteria of overlapping SNPs at CpG
probes, probes which map to multiple locations and repeats on
the 450K array. These CpGs were not removed at an earlier stage
as they may still warrant further evaluations by other studies,
although all subsequent analyses in our pipeline require aggre-
gating multiple CpGs together. The DEPICT method (data-driven
expression-prioritized integration for complex traits) (26) was
used to prioritize genes for all remaining variants. Variants
which were not allocated a likely impacted gene by DEPICT
were annotated with their nearest gene using bedtools (66).
Pathway and gene ontology enrichment
Genes implicated in the previous evaluations were tested for
enrichment of functional pathways and gene ontology terms
using ConsensusPathDB (27). When multiple genes were impli-
cated at the same association signal we used annotations
according to DEPICT over the nearest gene. All results which
had a false discovery rate < 5% were reported.
Identifying known and candidate genes for therapeutic intervention
We consulted the ChEMBL database (28) (version 23 accessed on
13 June 2017) to ascertain whether any of the implicated genes
encode proteins for known targets of approved drugs or com-
pounds in development.
Tissue-specific enrichment for CpG sites
The hypergeometric test was used to test for enrichment of impli-
cated CpG sites for histone mark peaks and regions of DNAse I in
up to 113 different tissue and cell types from the Encyclopedia of
DNA Elements (ENCODE) and Roadmap Epigenomics projects. To
calibrate background expectations, we randomly selected CpG
sites across the epigenome which resided in similar genomic
regions based on Illumina annotations (i.e. CpG island, gene body
etc.). We used permutations to control for multiple testing by ran-
domly selecting the same number of implicated CpG sites
matched on location and then repeating the enrichment compu-
tation for 10 000 iterations. This analysis was repeated using regu-
latory annotations from the Illumina 450K file (enhancer regions)
and Ensembl (promoters, open chromatin regions, transcriptional
repressor CTCF sites and transcription factor binding sites).
Supplementary Material
Supplementary Material is available at HMG online.
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